Literature DB >> 8257062

Human leucocyte antigen DNA typing in Singaporean Chinese patients with Graves' disease.

S H Chan1, Y N Lin, G B Wee, E C Ren, K F Lui, J S Cheah.   

Abstract

Human Leucocyte Antigen (HLA) A, B, C, DR, DQ and DP locus alleles in 35 Chinese patients with Graves' disease and 80 controls were typed for using serological and DNA polymerase chain reaction/sequence specific oligonucleotide (PCR/SSO) methods. B46 was found to be strongly associated with male patients (p = 0.0002; RR = 8.2, 95% confidence interval 2.1-32.2). In HLA class 1 alleles, besides B46, the frequencies of A2 and Cw1 were increased and A24 and B63 decreased in patients compared to controls. In HLA class 2 alleles, the frequencies of DRB1*1602, *0301, *1405, DRB5*02, DQB1*0502 were increased and DRB1*1501, DQB1*0301 decreased in patients.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8257062

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  4 in total

1.  Actual Associations between HLA Haplotype and Graves' Disease Development.

Authors:  Katarzyna Zawadzka-Starczewska; Bogusław Tymoniuk; Bartłomiej Stasiak; Andrzej Lewiński; Magdalena Stasiak
Journal:  J Clin Med       Date:  2022-04-29       Impact factor: 4.964

Review 2.  The HLA gene complex in thyroid autoimmunity: from epidemiology to etiology.

Authors:  Eric M Jacobson; Amanda Huber; Yaron Tomer
Journal:  J Autoimmun       Date:  2008-01-04       Impact factor: 7.094

3.  Strong Correlation between HLA and Clinical Course of Subacute Thyroiditis-A Report of the Three Siblings.

Authors:  Magdalena Stasiak; Andrzej Lewiński
Journal:  Genes (Basel)       Date:  2020-10-29       Impact factor: 4.096

4.  Association between HLA-B*46 allele and Graves disease in Asian populations: a meta-analysis.

Authors:  Yiping Li; Yufeng Yao; Man Yang; Li Shi; Xianli Li; Ying Yang; Ying Zhang; Chunjie Xiao
Journal:  Int J Med Sci       Date:  2013-01-03       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.